Chimeric antigen receptor and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12371466-B2
Application number	US-202017115565-A
Country	US
Kind code	B2
Filing date	Dec 8, 2020
Priority date	Feb 15, 2013
Publication date	Jul 29, 2025
Grant date	Jul 29, 2025

Abstract

The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

First claim

What is claimed is:

1. One or more nucleic acids comprising a nucleotide sequence(s) encoding a heterodimeric chimeric antigen receptor (CAR) comprising:
a first polypeptide comprising a first member of a dimerization pair, a first transmembrane domain, and an intracellular signaling domain; and
a second polypeptide comprising a scFv or VHH domain that specifically binds to mesothelin, a second member of the dimerization pair, and a second transmembrane domain;
wherein:
the first and second members of the dimerization pair are intracellular,
a dimerizing agent dimerizes the heterodimeric CAR when the first and second polypeptides are expressed by a cell with the dimerizing agent bound between the dimerization pair members of the first and second polypeptides,
the first polypeptide does not comprise an antigen-binding domain and the second polypeptide does not comprise an intracellular signaling domain capable of inducing cell activation, and
activation of the cell by the formed heterodimeric CAR binding mesothelin or said antigen is increased as compared to activation of the cell in the absence of the dimerizing agent.

2. The one or more nucleic acids according to claim 1 , wherein the intracellular signaling domain is a CD3-zeta intracellular signaling domain or a ZAP-70 intracellular signaling domain.

3. The one or more nucleic acids according to claim 1 , wherein the intracellular signaling domain comprises an immunoreceptor tyrosine-based activation motif (ITAM).

4. The one or more nucleic acids according to claim 1 , wherein the first polypeptide, the second polypeptide or both comprise an intracellular costimulatory polypeptide.

5. The one or more nucleic acids according to claim 1 , wherein the intracellular costimulatory polypeptides are selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.

6. The one or more nucleic acids according to claim 1 , wherein the first polypeptide comprises a first costimulatory polypeptide comprising an amino acid sequence and the second polypeptide comprises a second costimulatory polypeptide comprising an amino acid sequence that has at least 95% amino acid identity to the amino acid sequence of the first costimulatory polypeptide in the first polypeptide.

7. The one or more nucleic acids according to claim 1 , wherein the dimerizer agent is selected from the group consisting of: rapamycin, coumermycin, methotrexate, AP20187, abscisic acid, gibberellin and analogs thereof.

8. The one or more nucleic acids according to claim 1 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP-rapamycin associated protein (FRB);
b) a Gibberellic Acid Insensitive (GAI) protein and a gibberellin receptor (GID1) protein;
c) FKBP and calcineurin catalytic subunit A (CnA);
d) an abscisic acid receptor (PYL) protein and an abscissic acid insensitive (ABI) protein; and
e) FKBP and cyclophilin.

9. The one or more nucleic acids according to claim 1 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP;
b) gyrase B (GyrB) and GyrB;
c) dihydrofolate reductase (DHFR) and DHFR; and
d) DmrB and DmrB.

10. An isolated cell comprising the one or more nucleic acids according to claim 1 .

11. The isolated cell according to claim 10 , wherein the isolated cell is an immune cell.

12. The isolated cell according to claim 11 , wherein the immune cell is a lymphocyte or a NK cell.

13. The isolated cell according to claim 10 , wherein the cell is a human cell.

Assignees

• Univ California

Inventors

• Wu Chia-Yung
• Onuffer James
• Lim Wendell A

Classifications

• C12N2510/00

  Genetically modified cells · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• C12N9/14

  Hydrolases (3) · CPC title

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title

• C07K14/70575

  NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525) · CPC title